ALGN Stock Recent News

Undoubtedly, investors seem to have a new appetite for next-level revenue growth. Generative AI, GLP-1 weight-loss drugs and other breakthrough innovations (I'm not sure if the metaverse qualifies right now) seek to expand in some pretty massive markets.

Align Technology's (ALGN) first quarter 2024 revenue growth was up across all regions and was driven by strong Clear Aligner volumes, primarily in the Asia Pacific region.

The headline numbers for Align Technology (ALGN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Align Technology (ALGN) came out with quarterly earnings of $2.14 per share, beating the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $1.82 per share a year ago.

Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how BSX, TMO, ALGN and ICLR fare this time.

Align Technology's (ALGN) first-quarter 2024 performance is likely to reflect the strength of the Clear Aligner and Systems & Services businesses.

Investors are optimistic about Align Technology (ALGN) driven by geographic expansion and upbeat guidance.

Align's (ALGN) Invisalign Palatal Expander system is now available in Australia and New Zealand for skeletal and dental expansion in growing patients.

Here is how Align Technology (ALGN) and atai Life Sciences N.V. (ATAI) have performed compared to their sector so far this year.

Investors remain optimistic about Align Technology (ALGN), backed by Invisalign's strong potential and impressive collaborations.